Cytek Biosciences, Inc. 2026 Annual Meeting of Stockholders

Cytek Biosciences, Inc. held its 2026 annual meeting of stockholders on June 10, 2026. The meeting saw a turnout of approximately 86.1% of the outstanding common stock. Key outcomes include the election of Class II Directors Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to serve until the 2029 annual meeting. Stockholders also approved, on an advisory basis, the executive compensation for the year ended December 31, 2025. Furthermore, the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.